nach oben

Erschienen in:

01.10.2023 | Clinical study

HER2-targeted antibody-drug conjugates: no increase in risk of fatal AEs

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Treatment with antibody-drug conjugates (ADCs; immunoconjugates) that target human epidermal growth factor receptor 2 (HER2) does not appear to increase the risk of fatal adverse events (AEs) in patients with breast or gastric cancer, according to findings of a systematic review and meta-analysis published in BMC Cancer . …

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials BMC Cancer : 10 Oct 2023. Available from: URL: https://doi.org/10.1186/s12885-023-11250-1

Titel: HER2-targeted antibody-drug conjugates: no increase in risk of fatal AEs
Publikationsdatum: 01.10.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-47734-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Methylprednisolone/pembrolizumab

Mitragyna-speciosa

Risperidone

Multiple drugs

Multiple drugs

Azathioprine/cyclophosphamide